Objective: To investigate the therapeutic effect of 125IUdR on gliomas.
Methods: By means of growth-curve, clonogenic formation experiment and MTT assay, the inhibitive effect of 125IUdR on the proliferation of C6 cells was studied in vitro. Wistar rats with intracerebral C6 gliomas were used to verify the therapeutic efficacy of 125IUdR in vivo.
Results: C6 monolayer cells were efficiently inhibited by 125IUdR in a time-and-dose-dependent manner. In the MTT assay, after treament with 150 kBq/ml 125IUdR for 5 days, the inhibition rate reached 93.06%. In murine transplantable tumor, 125IUdR had significant therapeutic effect on rats bearing solid tumor glioma C6. After treatment with 125IUdR for 5 days, the tumor weight of experiment group was lower than that of blank group and control group (P<0.01). The median survival of animals treated with 125IUdR (27 days) was markedly longer than that of control group (9 days) (P<0.01). Na 125I and 127IUdR showed little inhibitive effect on the proliferation of C6 cells in vitro and in vivo.
Conclusion: 125IUdR can markedly inhibit the growth of Glioma cell line C6. 125IUdR has potential for the treatment of malignant brain tumor.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
FASN inhibition shows the potential for enhancing radiotherapy outcomes by targeting glycolysis, AKT, and ERK pathways in breast cancer.
Int J Radiat Biol
January 2025
Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei City, Taiwan.
Purpose: Breast cancer ranks as the most prevalent cancer in women, characterized by heightened fatty acid synthesis and glycolytic activity. Fatty acid synthase (FASN) is prominently expressed in breast cancer cells, regulating fatty acid synthesis, thereby enhancing tumor growth and migration, and leading to radioresistance. This study aims to investigate how FASN inhibition affects cell proliferation, migration, and radioresistance in breast cancer, as well as the mechanisms involved.
View Article and Find Full Text PDFCerebral blood flow and histological analysis for the accurate differentiation of infiltrating tumor and vasogenic edema in glioblastoma.
PLoS One
January 2025
Department of Neurosurgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Background: Glioblastoma is characterized by neovascularization and diffuse infiltration into the adjacent tissue. T2*-based dynamic susceptibility contrast (DSC) MR perfusion images provide useful measurements of the biomarkers associated with tumor perfusion. This study aimed to distinguish infiltrating tumors from vasogenic edema in glioblastomas using DSC-MR perfusion images.
View Article and Find Full Text PDFIn Vitro Experiment Present ROCK2 Inhibition Promotes the Therapeutic Effect of Bevacizumab in the Treatment of Glioblastoma Multiforme.
Clin Neuropharmacol
January 2025
Department of Neurosurgery, Yubei District Hospital of TCM, Chongqing, China.
Objective: Gliomas are a general designation for neuroepithelial tumors derived from the glial cells of the central nervous system. According to the histopathological and immunohistochemical features, the World Health Organization classifies gliomas into four grades. Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor that has been approved for the treatment of glioblastoma multiforme (GBM) as a second-line therapy.
View Article and Find Full Text PDFOsteogenic potential of silver nanoparticles in critical sized mandibular bone defects: an experimental study in white albino rats.
Odontology
January 2025
Oral Biology Department, Faculty of Dentistry, Mansoura University, Mansoura, Egypt.
Natural bone is a self-regenerating nanocomposite made of proteins and minerals. Such self-regenerative capacity can be negatively affected by certain diseases involving the bone or its surrounding tissues. Our study assesses the ability of bone grafting material to regenerate bone in animals who have artificially created critical-sized defects.
View Article and Find Full Text PDFEndoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell lung cancer: a cellular study.
Cancer Chemother Pharmacol
January 2025
Institute of Medicine, Chung-Shan Medical University, Taichung, 40201, Taiwan.
Objective: Based on our previous research, which demonstrated that elevated plasma endoglin (ENG) levels in lung cancer patients were associated with a better prognosis, increased sensitivity to pemetrexed, and enhanced tumor suppression, this study aims to validate these findings at the cellular level. The focus is on membrane and extracellular ENG and their influence on drug response and tumor cell behavior in non-small cell lung cancer (NSCLC) cells.
Methods: The correlation between ENG expression and pemetrexed-induced cytotoxicity in eight human non-squamous subtype NSCLC cell lines was analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!